Sermorelin
Also known as: GRF 1-29 · GHRH (1-29)
The first 29 residues of human growth-hormone-releasing hormone — the shortest fragment retaining full activity at the GHRH receptor. Has held marketing authorisation as a diagnostic and therapeutic agent.
Development status: Approved as a medicine in one or more jurisdictions
Identifiers and molecular characteristics
- CAS number
- Not verified
- Molecular formula
- Not verified
- Molecular mass
- Not verified
- Amino-acid sequence
- Not verified
- PubChem CID
- Not verified
Identifiers are published only with a source and a check date. Fields marked “not verified” have not yet been confirmed against a primary source — we show the gap rather than an unchecked figure. Always confirm against the certificate of analysis for the specific lot you hold.
Biological targets
- GHRH receptor
Mechanism of action
Native GHRH is 44 residues; biological activity resides in the N-terminal 29, which is what sermorelin is. Short half-life, because it is unmodified and susceptible to DPP-4 cleavage.
Research evidence and its limits
Clinical use and published trials, principally in growth hormone deficiency assessment.
Safety considerations
Where approved, product labelling from the relevant regulator is the authoritative source. Supplied and discussed here strictly as a laboratory research material. Not a medicine, not for human or veterinary administration, and nothing on this page should be read as a dosing, treatment or safety recommendation.
Analytical identification and quality testing
Identity by high-resolution mass spectrometry against the expected mass, purity by RP-HPLC with UV detection. For a sequence-defined peptide, enzymatic digestion followed by peptide mapping gives far stronger identity evidence than mass alone, because isomers and closely related sequences can share a mass.
Regulatory status
Has held approval in some jurisdictions; availability has varied over time. Verify current status.
References
Related compounds
CJC-1295
A growth-hormone-releasing hormone analogue. The name is used for two materially different compounds — one bearing a drug-affinity complex (DAC) that greatly extends half-life, and one without it — and conflating them is the most common error in writing about this molecule.
Tesamorelin
A stabilised GHRH analogue carrying a trans-3-hexenoyl group at the N-terminus, approved in some jurisdictions for a specific indication.
Entry last reviewed 2026-10-11. Regulatory status and scientific understanding change; verify against primary sources before relying on anything here.